

Hansjakob Furrer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3053895/hansjakob-furrer-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

309
papers

16,277
citations

65
h-index

117
g-index

333
ext. papers

18,105
ext. citations

6.4
avg, IF

5.69
L-index

#	Paper	IF	Citations
309	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021 , 73, 195-202	11.6	2
308	How do healthcare providers construe patient complexity? A qualitative study of multimorbidity in HIV outpatient clinical practice. <i>BMJ Open</i> , 2021 , 11, e051013	3	
307	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2134-e2141	11.6	3
306	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 758-767	8	22
305	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Antigens. <i>Frontiers in Immunology</i> , 2021 , 12, 620622	8.4	2
304	Importance of critical care staffing and standard intensive care therapy in the COVID-19 era: a descriptive study of the first epidemic wave at a Swiss tertiary intensive care unit. <i>Swiss Medical Weekly</i> , 2021 , 151, w20529	3.1	1
303	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021 , 24, e25726	5.4	2
302	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1413-1421	11.6	0
301	Dissemination of is associated to a null variant that limits antigen exchange via trafficking extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021 , 10, e12046	16.4	2
300	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021 , 11, 4586	4.9	2
299	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2021 ,	7	1
298	Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2681-2689	5.1	1
297	Rate of treatment success and associated factors in the program for drug-susceptible tuberculosis in the Forest Region, Republic of Guinea, 2010-2017: A real-world retrospective observational cohort study. <i>International Journal of Infectious Diseases</i> , 2021 , 110, 6-14	10.5	
296	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab032	1	5
295	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
294	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2021 ,	7.8	6
293	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2021 , 76, 893-897	11.6	4

292	Is real time PCR preferable to the direct immunofluorescence in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected patients?. <i>BMC Research Notes</i> , 2020 , 13, 235	2.3	5
291	Think tuberculosis-but is thinking enough?. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 639-640	25.5	2
290	Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25460	5.4	8
289	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020 , 222, 637-645	7	10
288	Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant With Tigecycline Monotherapy. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz551	1	1
287	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz464 ¹		5
286	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. <i>PLoS Biology</i> , 2020 , 18, e3000963	9.7	0
285	Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study. <i>HIV Medicine</i> , 2020 , 21, 53-63	2.7	7
284	Smartphone App and Carbon Monoxide Self-Monitoring Support for Smoking Cessation: A Randomized Controlled Trial Nested into the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, e8-e11	3.1	0
283	Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study ¹ . <i>Journal of Travel Medicine</i> , 2020 , 27,	12.9	3
282	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 227-232	3.1	3
281	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. <i>Clinical Infectious Diseases</i> , 2020 , 70, 297-303	11.6	9
280	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
279	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
278	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
277	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
276	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
275	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		

274	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. <i>Studies in Health Technology and Informatics</i> , 2020 , 270, 1163-1167	0.5	0
273	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019 , 38, 2428-2446	2.3	10
272	Gradual Evolution of Cefepime Resistance in an ST131 Strain Expressing a Plasmid-Encoded CMY-2 β -Lactamase. <i>Frontiers in Microbiology</i> , 2019 , 10, 1311	5.7	6
271	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. <i>BMC Infectious Diseases</i> , 2019 , 19, 834	4	3
270	Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. <i>Mycoses</i> , 2019 , 62, 1127-1132	5.2	4
269	Imaging patterns of <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive and renal transplant patients - a multicentre study. <i>Swiss Medical Weekly</i> , 2019 , 149, w20130	3.1	3
268	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm ³ : Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, 10-17	3.1	8
267	IL-4 polymorphism influences susceptibility to <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive patients. <i>Aids</i> , 2019 , 33, 1719-1727	3.5	6
266	Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 205-213	3.1	12
265	Fewer pills do not mean fewer drug-drug interactions: severe rhabdomyolysis on Elvitegravir/Cobicistat and statin treatment. <i>Aids</i> , 2018 , 32, 676-678	3.5	4
264	Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy072	1	5
263	Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1099-1108	11.6	12
262	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. <i>Journal of Infection</i> , 2018 , 76, 44-54	18.9	7
261	Intestinal colonisation with extended-spectrum cephalosporin-resistant Enterobacteriaceae in different populations in Switzerland: prevalence, risk factors and molecular features. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 12, 17-19	3.4	10
260	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. <i>Aids</i> , 2018 , 32, 2759-2765	3.5	5
259	Fatal Measles Virus Infection After Rituximab-Containing Chemotherapy in a Previously Vaccinated Patient. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy244	1	3
258	Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 519-521	14.3	8
257	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV, the</i> , 2017 , 4, e251-e259	7.8	9

256	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1316-1326	11.6	23
255	Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2069-2074	5.1	5
254	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. <i>PLoS ONE</i> , 2017 , 12, e0180983	3.7	19
253	Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. <i>Aids</i> , 2017 , 31, 427-436	3.5	123
252	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. <i>International Journal of Epidemiology</i> , 2017 , 46, 797-797n	7.8	17
251	First two cases of severe multifocal infections caused by <i>Klebsiella pneumoniae</i> in Switzerland: characterization of an atypical non-K1/K2-serotype strain causing liver abscess and endocarditis. <i>Journal of Global Antimicrobial Resistance</i> , 2017 , 10, 165-170	3.4	3
250	Awareness and management of elevated blood pressure among human immunodeficiency virus-infected adults receiving antiretroviral therapy in urban Zambia: a call to action. <i>Global Health Action</i> , 2017 , 10, 1359923	3	2
249	Adverse events of raltegravir and dolutegravir. <i>Aids</i> , 2017 , 31, 1853-1858	3.5	68
248	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 453-460	11.3	15
247	Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. <i>Aids</i> , 2017 , 31, 61-70	3.5	46
246	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017 , 66, 297-303	13.4	58
245	Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. <i>Biometrics</i> , 2017 , 73, 294-304	1.8	7
244	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21327	5.4	23
243	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017 , 6,	8.9	13
242	Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study. <i>PLoS ONE</i> , 2017 , 12, e0172089	3.7	30
241	Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. <i>Swiss Medical Weekly</i> , 2017 , 147, w14485	3.1	21
240	Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016 , 64, 1856-1869	11.2	61
239	Bactericidal activity of penicillin, ceftriaxone, gentamicin and daptomycin alone and in combination against <i>Aerococcus urinae</i> . <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 271-6	14.3	8

238	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016 , 95, e5094	1.8	19
237	Immune recovery in HIV-infected patients after <i>Candida</i> esophagitis is impaired despite long-term antiretroviral therapy. <i>Aids</i> , 2016 , 30, 1923-33	3.5	5
236	Travellers returning ill from the tropics - a descriptive retrospective study. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2016 , 2, 6	3.2	1
235	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw022	1	12
234	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1352-60	5.1	3
233	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV, the</i> , 2016 , 3, e120-31	7.8	42
232	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1310-1317	11.6	39
231	Clonal analysis of <i>Aerococcus</i> <i>urinae</i> isolates by using the repetitive extragenic palindromic PCR (rep-PCR). <i>Journal of Infection</i> , 2016 , 72, 262-5	18.9	2
230	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 115-122	11.6	43
229	Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. <i>Swiss Medical Weekly</i> , 2016 , 146, w14348	3.1	27
228	Update of the Swiss guidelines on post-treatment Lyme disease syndrome. <i>Swiss Medical Weekly</i> , 2016 , 146, w14353	3.1	12
227	Polyclonal Intestinal Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae upon Traveling to India. <i>Frontiers in Microbiology</i> , 2016 , 7, 1069	5.7	22
226	Clinical Course, Radiological Manifestations, and Outcome of <i>Pneumocystis jirovecii</i> Pneumonia in HIV Patients and Renal Transplant Recipients. <i>PLoS ONE</i> , 2016 , 11, e0164320	3.7	19
225	The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 302-9	3.1	13
224	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw162	1	16
223	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. <i>Scientific Reports</i> , 2016 , 6, 27580	4.9	14
222	Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. <i>International Journal of Infectious Diseases</i> , 2016 , 46, 8-10	10.5	15
221	Multiplex Real-Time PCR Assay with High-Resolution Melting Analysis for Characterization of Antimicrobial Resistance in <i>Neisseria gonorrhoeae</i> . <i>Journal of Clinical Microbiology</i> , 2016 , 54, 2074-81	9.7	25

220	Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 1862-1870	9.7	70
219	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016 , 18, 814-22	8.1	25
218	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1245-1253	11.6	15
217	In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1605-11	5.9	37
216	In vitro susceptibility of Aerococcus urinae isolates to antibiotics used for uncomplicated urinary tract infection. <i>Journal of Infection</i> , 2015 , 71, 395-7	18.9	9
215	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV,the</i> , 2015 , 2, e335-43	7.8	41
214	Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. <i>Travel Medicine and Infectious Disease</i> , 2015 , 13, 192-6	8.4	20
213	Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 68, 568-77	3.1	31
212	Tracking a tuberculosis outbreak over 21 years: strain-specific single-nucleotide polymorphism typing combined with targeted whole-genome sequencing. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1306-16	7	72
211	Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2015 , 20, 165-75	1.6	26
210	Burden of serious fungal infections in Tanzania. <i>Mycoses</i> , 2015 , 58 Suppl 5, 70-9	5.2	27
209	Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. <i>The Cochrane Library</i> , 2015 , CD006150	5.2	49
208	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. <i>Aids</i> , 2015 , 29, 2195-200	3.5	47
207	The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. <i>Aids</i> , 2015 , 29, 2509-15	3.5	60
206	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20317	5.4	41
205	A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. <i>PLoS ONE</i> , 2015 , 10, e0123275	3.7	19
204	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. <i>PLoS ONE</i> , 2015 , 10, e0145380	3.7	13
203	Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. <i>Journal of NeuroVirology</i> , 2015 , 21, 694-701	3.9	18

202	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv026	1	17
201	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv046	1	55
200	Increases in Condomless Sex in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv077		26
199	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 930-40	5.1	86
198	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. <i>Cancer</i> , 2015 , 121, 423-31	6.4	28
197	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015 , 212, 28-38	7	49
196	HIV-Infektion 2015 , 1-15		
195	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015 , 20,	19.8	55
194	Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2363-8	5.9	26
193	Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1312-21	11.6	107
192	Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998-2012): emergence of multidrug-resistant clones less susceptible to cephalosporins. <i>BMC Infectious Diseases</i> , 2014 , 14, 106	4	32
191	Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 260-2	14.3	49
190	Chameleons everywhere. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	8
189	Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. <i>HIV Clinical Trials</i> , 2014 , 15, 92-103		4
188	Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19505	5.4	6
187	AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19621	5.4	1
186	The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19561	5.4	1
185	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , 2014 , 43, 166-77	13.6	25

184	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. <i>Aids</i> , 2014 , 28, 2231-9	3.5	19
183	Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014 , 58, 285-94	11.6	67
182	High colonization rates of extended-spectrum β -lactamase (ESBL)-producing <i>Escherichia coli</i> in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. <i>BMC Infectious Diseases</i> , 2014 , 14, 528	4	84
181	The IFNL3/4 Δ variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. <i>Aids</i> , 2014 , 28, 1885-9	3.5	34
180	Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals. <i>Antiviral Therapy</i> , 2014 , 19, 149-59	1.6	11
179	Sexually transmitted infections in HIV-infected people in Switzerland: cross-sectional study. <i>PeerJ</i> , 2014 , 2, e537	3.1	8
178	In vitro activity of clinically implemented β -lactams against <i>Aerococcus urinae</i> : presence of non-susceptible isolates in Switzerland. <i>New Microbiologica</i> , 2014 , 37, 563-6	1.1	9
177	Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1659-66	5.6	46
176	Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1454-8	7	57
175	TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. <i>BioMed Research International</i> , 2013 , 2013, 373601	3	7
174	The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. <i>PLoS Computational Biology</i> , 2013 , 9, e1003203	5	17
173	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013 , 10, e1001510	11.6	212
172	HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. <i>PLoS Genetics</i> , 2013 , 9, e1003318	6	61
171	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , 2013 , 207, 759-67	7	6
170	The incidence of AIDS-defining illnesses at a current CD4 count \geq 200 cells/ μ l in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1038-47	11.6	79
169	Risk of tuberculosis following HIV seroconversion in high-income countries. <i>Thorax</i> , 2013 , 68, 207-13	7.3	22
168	Emergence of extensively drug-resistant <i>Haemophilus parainfluenzae</i> in Switzerland. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2867-9	5.9	27
167	Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1102-12	7	30

166	Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013 , 13, 471	4	58
165	Dog bite injuries: primary and secondary emergency department presentations--a retrospective cohort study. <i>Scientific World Journal, The</i> , 2013 , 2013, 393176	2.2	27
164	The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2013 , 18, 337-44	1.6	20
163	Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2013 , 8, e77691	3.7	35
162	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 9-18	1.9	25
161	Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. <i>PLoS ONE</i> , 2012 , 7, e37983	3.7	11
160	Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. <i>PLoS ONE</i> , 2012 , 7, e50307	3.7	14
159	Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3047-53	5.9	80
158	CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. <i>PLoS Medicine</i> , 2012 , 9, e1001194	11.6	119
157	Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1364-72	11.6	53
156	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. <i>Archives of Internal Medicine</i> , 2012 , 172, 1313-21		26
155	Incidence of HIV-1 drug resistance among antiretroviral treatment-naïve individuals starting modern therapy combinations. <i>Clinical Infectious Diseases</i> , 2012 , 54, 131-40	11.6	30
154	Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 388-95	9.7	37
153	Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1408-16	11.6	191
152	Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 79-85	3.1	25
151	Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, 135-42	3.1	21
150	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. <i>Aids</i> , 2012 , 26, 567-75	3.5	63
149	A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. <i>Clinical Nephrology</i> , 2012 , 77, 311-20	2.1	33

148	Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. <i>PLoS ONE</i> , 2011 , 6, e18578	3.7	14
147	A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011 , 6, e27903	3.7	16
146	Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?. <i>Aids</i> , 2011 , 25, 876-8	3.5	12
145	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. <i>BMC Infectious Diseases</i> , 2011 , 11, 319	4	25
144	Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. <i>BMC Infectious Diseases</i> , 2011 , 11, 98	4	23
143	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011 , 53, 1446-54	11.2	53
142	No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipodystrophy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 620-4	7	10
141	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. <i>Aids</i> , 2011 , 25, 441-51	3.5	30
140	Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. <i>Aids</i> , 2011 , 25, 2149-55	3.5	39
139	Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. <i>Aids</i> , 2011 , 25, 2306-8	3.5	5
138	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2107-11	5.1	109
137	Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1130-9	11.6	433
136	Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. <i>Journal of Infectious Diseases</i> , 2011 , 203, 246-57	7	80
135	Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. <i>Tropical Medicine and International Health</i> , 2010 , 15, 567-73	2.3	18
134	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 217-30	1.9	91
133	Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 197-203	3.1	83
132	Is it safe to discontinue primary <i>Pneumocystis jiroveci</i> pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count. <i>Clinical Infectious Diseases</i> , 2010 , 51, 611-9	11.6	81
131	Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1090-8	11.6	21

130	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010 , 59, 1252-8	19.2	39
129	Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1488-97	7	145
128	Cohort profile: the Swiss HIV Cohort study. <i>International Journal of Epidemiology</i> , 2010 , 39, 1179-89	7.8	282
127	Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. <i>Clinical Infectious Diseases</i> , 2010 , 50, 473-80	11.6	84
126	Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. <i>PLoS Pathogens</i> , 2010 , 6, e1001123	7.6	91
125	Possible role of anti-TNF monoclonal antibodies in the treatment of <i>Mycobacterium marinum</i> infection. <i>Rheumatology</i> , 2010 , 49, 1991-3	3.9	12
124	Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 464-71	3.1	16
123	Yellow fever vaccination in HIV-infected patients. <i>HIV Therapy</i> , 2010 , 4, 17-26		13
122	Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. <i>Gastroenterology</i> , 2010 , 138, 1338-45, 1345.e1-7	13.3	956
121	Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , 2010 , 10, 251-61	25.5	527
120	Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. <i>Aids</i> , 2010 , 24, 1907-16	3.5	41
119	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010 , 15, 413-23	1.6	134
118	Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010 , 170, 57-65		111
117	A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2010 , 29, 2757-68	2.3	45
116	Effects of HIV type-1 immune selection on susceptibility to integrase inhibitor resistance. <i>Antiviral Therapy</i> , 2009 , 14, 953-64	1.6	4
115	Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1402-12	11.6	65
114	Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009 , 48, 979-87	11.6	41
113	Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1138-51	11.6	90

112	Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. <i>Circulation: Cardiovascular Genetics</i> , 2009 , 2, 621-8		32
111	Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2009 , 48, 659-66	11.6	96
110	Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. <i>Hepatology</i> , 2009 , 49, 1069-82	11.2	115
109	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009 , 50, 1017-29	11.2	50
108	Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 632-41	5.7	13
107	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009 , 23, 2199-208	3.5	33
106	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. <i>Aids</i> , 2009 , 23, 2485-95	3.5	30
105	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 300-9	1.9	122
104	Specific immunotherapy in a pollen-allergic patient with human immunodeficiency virus infection. <i>World Allergy Organization Journal</i> , 2009 , 2, 57-8	5.2	10
103	Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. <i>PLoS ONE</i> , 2009 , 4, e8275	3.7	16
102	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009 , 14, 349-57	1.6	22
101	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009 , 14, 349-357	1.6	32
100	The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. <i>Journal of Infectious Diseases</i> , 2008 , 198, 864-7	7	85
99	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>Aids</i> , 2008 , 22, 301-6	3.5	107
98	Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. <i>Aids</i> , 2008 , 22, 1019-28	3.5	49
97	Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1685-94	7	83
96	Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1299-309	11.6	29
95	HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1921-5	11.6	24

94	CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1093-101	11.6	41
93	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008 , 22, 767-75	3.5	35
92	Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. <i>PLoS Medicine</i> , 2008 , 5, e148	11.6	99
91	Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. <i>Antiviral Therapy</i> , 2008 , 13, 77-85	1.6	26
90	Low Current and Nadir CD4+ T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008 , 13, 455-460	1.6	9
89	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008 , 13, 1019-1028	1.6	21
88	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. <i>Antiviral Therapy</i> , 2008 , 13, 77-86	1.6	81
87	Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2007 , 45, 111-9	11.6	201
86	Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. <i>HIV Clinical Trials</i> , 2007 , 8, 77-85		7
85	Reply to Hamlyn et al. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1394-1395	11.6	1
84	Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. <i>Archives of Internal Medicine</i> , 2007 , 167, 1782-90		95
83	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2007 , 81, 8846-8848	6.6	1
82	Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 755-64	1.9	60
81	Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. <i>Clinical Infectious Diseases</i> , 2007 , 44, 94-102	11.6	94
80	Effect of tenofovir on renal glomerular and tubular function. <i>Aids</i> , 2007 , 21, 1483-5	3.5	33
79	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007 , 21, 2201-7	3.5	6
78	Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , 2007 , 7, 607-13	25.5	384
77	Does tenofovir influence efavirenz pharmacokinetics?. <i>Antiviral Therapy</i> , 2007 , 12, 115-8	1.6	6

76	Late presentation of HIV-infected individuals. <i>Antiviral Therapy</i> , 2007 , 12, 841-51	1.6	24
75	CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007 , 12, 889-97	1.6	11
74	Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. <i>Antiviral Therapy</i> , 2007 , 12, 1157-64	1.6	18
73	Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007 , 12, 1165-73	1.6	44
72	Hypogonadism in HIV-1-Infected Men is common and does not resolve during antiretroviral therapy. <i>Antiviral Therapy</i> , 2007 , 12, 261-266	1.6	50
71	Late Presentation of HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2007 , 12, 841-851	1.6	34
70	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007 , 12, 931-940	1.6	20
69	CD4+ T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007 , 12, 889-898	1.6	18
68	Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007 , 12, 1165-1174	1.6	75
67	Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification. <i>Antiviral Therapy</i> , 2007 , 12, 1157-1164	1.6	24
66	Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. <i>Journal of Virology</i> , 2006 , 80, 11094-104	6.6	98
65	CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. <i>Lancet, The</i> , 2006 , 368, 459-65	4.0	188
64	Adjunctive corticosteroids for <i>Pneumocystis jiroveci</i> pneumonia in patients with HIV-infection. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD006150		48
63	Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 385-92	3.1	141
62	Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome. <i>HIV Clinical Trials</i> , 2006 , 7, 48-54		0
61	A case of voluntary intoxication with efavirenz and lamivudine. <i>Aids</i> , 2006 , 20, 1352-4	3.5	6
60	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006 , 20, 889-94	3.5	45
59	Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 332-8	3.2	19

58	Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 307-18	6.1	55
57	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006 , 11, 131-142	1.6	22
56	HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 250-6	3.1	21
55	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005 , 19, 1987-94	3.5	25
54	Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 1-5	1.9	307
53	Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 599-608	1.9	69
52	Plasma leptin levels in men are not related to the development of lipotrophy during antiretroviral therapy. <i>Aids</i> , 2005 , 19, 1837-42	3.5	11
51	Adjunctive corticosteroids for <i>Pneumocystis jiroveci</i> pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. <i>BMC Infectious Diseases</i> , 2005 , 5, 101	4	29
50	Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1419-26	7	92
49	Characteristics, determinants, and clinical relevance of CD4 T cell recovery to . <i>Clinical Infectious Diseases</i> , 2005 , 41, 361-72	11.6	257
48	Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 891-913	4	9
47	Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2005 , 41, 395-402	11.6	173
46	Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1381-6	7	163
45	Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 38, 238-40	3.1	36
44	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005 , 10, 585-591	1.6	67
43	Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. <i>BMJ, The</i> , 2004 , 328, 15	5.9	38
42	Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features. <i>AIDS Patient Care and STDs</i> , 2004 , 18, 665-75	5.8	21
41	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. <i>Aids</i> , 2004 , 18, 1521-7	3.5	22

40	Long-term safety of discontinuation of secondary prophylaxis against <i>Pneumocystis pneumonia</i> : prospective multicentre study. <i>Aids</i> , 2004 , 18, 2047-53	3.5	10
39	Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. <i>Aids</i> , 2004 , 18, 2213-5	3.5	12
38	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. <i>Blood</i> , 2004 , 104, 1784-92	2.2	42
37	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004 , 9, 263-274	1.6	5
36	Infrequent Transmission of HIV-1 Drug-Resistant Variants. <i>Antiviral Therapy</i> , 2004 , 9, 375-384	1.6	40
35	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. <i>Aids</i> , 2003 , 17, 2237-44	3.5	61
34	Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. <i>Aids</i> , 2003 , 17, F33-7	3.5	68
33	Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 494-9	3.1	57
32	A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. <i>Archives of Internal Medicine</i> , 2003 , 163, 1220-6		129
31	Herpes simplex virus hepatitis 4 years after liver transplantation. <i>Journal of Gastroenterology</i> , 2003 , 38, 1005-8	6.9	27
30	Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma. <i>Ophthalmology</i> , 2003 , 110, 432-6	7.3	18
29	CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. <i>Archives of Internal Medicine</i> , 2003 , 163, 2187-95		284
28	Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of <i>Pneumocystis carinii</i> pneumonia prophylaxis. <i>Clinical Infectious Diseases</i> , 2003 , 36, 917-21	11.6	11
27	Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era. <i>Current Infectious Disease Reports</i> , 2002 , 4, 161-174	3.9	2
26	Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. <i>Journal of Clinical Immunology</i> , 2002 , 22, 253-62	5.7	13
25	A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. <i>Journal of Infectious Diseases</i> , 2002 , 185, 1251-60	7	121
24	Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. <i>Annals of Internal Medicine</i> , 2002 , 137, 239-50	8	98
23	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l. <i>Aids</i> , 2002 , 16, 1371-81	3.5	80

22	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. <i>Aids</i> , 2002 , 16, 747-55	3.5	36
21	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , 2002 , 359, 30-6	4.0	575
20	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002 , 16, 1967-9	3.5	88
19	Opportunistic infections: an update. <i>Journal of HIV Therapy</i> , 2002 , 7, 2-7		8
18	Chronic watery diarrhea due to co-infection with <i>Cryptosporidium</i> spp and <i>Cyclospora cayetanensis</i> in a Swiss AIDS patient traveling in Thailand. <i>Journal of Travel Medicine</i> , 2001 , 8, 143-5	12.9	7
17	Increased risk of wasting syndrome in HIV-infected travellers: prospective multicentre study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2001 , 95, 484-6	2	12
16	Discontinuation of secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. <i>New England Journal of Medicine</i> , 2001 , 344, 168-74	59.2	127
15	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet, The</i> , 2001 , 358, 1322-7	4.0	280
14	Discontinuation of primary prophylaxis in HIV-infected patients at high risk of <i>Pneumocystis carinii</i> pneumonia: prospective multicentre study. <i>Aids</i> , 2001 , 15, 501-7	3.5	20
13	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , 2001 , 15, 1793-800	3.5	33
12	Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. <i>Aids</i> , 2000 , 14, 243-9	3.5	54
11	Discontinuing or withholding primary prophylaxis against <i>Mycobacterium avium</i> in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , 2000 , 14, 1409-12	3.5	21
10	Prevalence and clinical significance of splenomegaly in asymptomatic human immunodeficiency virus type 1-infected adults. Swiss HIV cohort study. <i>Clinical Infectious Diseases</i> , 2000 , 30, 943-5	11.6	10
9	Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. <i>Lancet, The</i> , 2000 , 355, 2217-8	4.0	54
8	Discontinuation of primary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. <i>New England Journal of Medicine</i> , 1999 , 340, 1301-6	59.2	235
7	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 282, 2220-6	27.4	341
6	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. <i>Lancet, The</i> , 1999 , 353, 863-8	4.0	812
5	Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. <i>American Journal of Medicine</i> , 1999 , 106, 371-2	2.4	65

4	HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. <i>Aids</i> , 1999 , 13, 1857-62	3.5	84
3	Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. <i>Aids</i> , 1998 , 12, 1341-6	3.5	12
2	Inhibition of syncytia-inducing (SI) virus by autologous serum from HIV-1-infected individuals. <i>Clinical and Diagnostic Virology</i> , 1996 , 6, 127-35		
1	Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. <i>Aids</i> , 1994 , 8, 1307-13	3.5	38